![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 51, 49453-49458, December 20, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota 55455
Received for publication, September 11, 2002, and in revised form, October 15, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Granulocytic differentiation of human HL-60 cells
can be induced by retinoic acid and is accompanied by a massive
expression of CD38, a multi-functional enzyme responsible for
metabolizing cyclic ADP-ribose (cADPR), a Ca2+
messenger. Immunofluorescence staining showed that CD38 was expressed not only on the surface of intact HL-60 cells but also intracellularly, which was revealed after permeabilization with Triton. Concomitant with
CD38 expression was the accumulation of cADPR, and both time courses
preceded the onset of differentiation, suggesting a causal role for
CD38. Consistently, treatment of HL-60 cells with a permeant inhibitor
of CD38, nicotinamide, inhibited both the CD38 activity and
differentiation. More specific blockage of CD38 expression was achieved
by using morpholino antisense oligonucleotides targeting its mRNA,
which produced a corresponding inhibition of differentiation as well.
Similar inhibitory effects were observed when CD38 expression was
reduced by the RNA interference technique targeting two separate regions of the coding sequence of CD38. Further support came from transfecting HL-60 cells with a Tet-On expression vector containing a
full-length CD38. Subsequent treatments with doxycycline induced both
CD38 expression and differentiation in the absence of retinoic acid.
These results provide the first evidence that CD38 expression and the
consequential accumulation of cADPR play a causal role in mediating
cellular differentiation.
CD38, first defined by monoclonal antibody typing as an antigen
(1), has been widely used as a marker for lymphocyte differentiation. Sequence comparison reveals that it shares about 30% sequence identity
with the Aplysia ADP-ribosyl cyclase, indicating that it is
a mammalian homolog (2). This is later confirmed by studies showing
CD38 can indeed catalyze the cyclization of NAD to produce cyclic
ADP-ribose (cADPR)1 (reviewed
in Refs. 3 and 4), a cyclic nucleotide messenger active in mediating
Ca2+ signaling in a wide variety of cells spanning three
biological kingdoms: protist, plant, and animal (Refs. 5-7; reviewed
in Refs. 8 and 9). More remarkably, CD38 is, in fact, a
multi-functional enzyme capable of using a different substrate, NADP,
to catalyze a base exchange reaction (10) to produce nicotinic acid
adenine dinucleotide phosphate, another general Ca2+
messenger with a totally distinct structure and a separate mechanism of
action (Ref. 11; reviewed in Refs. 9 and 12). It is now known that CD38
is not specific for lymphocytes but is ubiquitously expressed in many
tissues and cells (reviewed in Ref. 3). The physiological functions
that involve CD38 are equally widespread and include, for example, cell
proliferation (13) and expansion of human hemopoietic progenitors (14,
15). CD38 knockout mice exhibit defects in neutrophil chemotaxis (16),
insulin secretion (reviewed in Ref. 17), and aberrant muscarinic
Ca2+ signaling in pancreatic acinar cells (18), indicating
the importance of CD38 in regulating functions in vivo as
well as in vitro.
A dramatic increase in CD38 expression accompanies granulocytic
differentiation induced by retinoic acid in human HL-60 cells (19-21).
The cell line is derived from a patient with acute promyelocytic leukemia and can be induced to differentiate in vitro to a
number of different cell types, such as granulocytes, monocytes, or
macrophages (22). It is a widely used model system for elucidating
hemopoietic differentiation (22, 23). In this study we present evidence that the CD38 expression may play a causal role in mediating the differentiation process in HL-60 cells.
Materials--
ADP-ribosyl cyclase was prepared by a yeast
expression system as described previously (24). Alcohol dehydrogenase
from yeast (suitable for cycling), activated charcoal, diaphorase from
Clostridium kluyveri, NAD+, nicotinamide,
nucleotide pyrophosphatase from Crotalus atrox venom, NADase
from Neurospora crassa, NBT, phorbol 12-myristate 13-acetate, resazurin, tri-n-octylamine Tris, and
1,1,2-trichlorotrifluoroethane were from Sigma. Alkaline phosphatase
from bovine intestine was obtained from Roche Molecular Biochemicals.
Centricon filters and Immobilon filter plates were from Millipore
(Bedford, MA). Alexa Fluor goat anti-mouse IgG was obtained from
Molecular Probes.
Culture of HL-60 Cells and Induction of
Differentiation--
HL-60 cells were obtained from the American Type
Culture Collection. The cells were maintained in suspension in RPMI
medium supplemented with 10% fetal calf bovine serum and kept at
37 °C in a 5% CO2 atmosphere. The cells were passaged
by dilution in fresh medium to a density of about 0.2 × 106 cells/ml. Prior to induction of differentiation by
retinoic acid (RA), the cells were maintained at a logarithmic growth
rate and seeded at a density of 0.2 × 106 cells/ml.
RA was added at a final concentration of 1 µM by dilution from a 10 mM stock solution prepared in Me2SO.
Control cells were treated with a similar dilution of
Me2SO, which was found to have no effect on the
differentiation or the rate of cell division. At the indicated times of
continuous exposure to RA, the cells were pelleted by centrifugation at
700 × g for 5 min. Differentiation of HL-60 cells was
measured by adding 1 ml of cell suspension (0.5-2 × 106 cells) to a solution containing 2 mg/ml of NBT and 20 ng/ml of phorbol myristate acetate in phosphate-buffered saline. The
incubation was allowed to proceed for 1 h at 37 °C and was
stopped by the addition of 0.4 ml of cold 2 M HCl. The
formazan product was obtained by centrifugation of the sample at
700 × g for 10 min. The supernatant was discarded, and
the formazan was dissolved in 1 ml of Me2SO. The absorbance
of the solution was measured at 590 nm. The data are expressed as
absorbance units/106 cells.
Fluorescence-activated Cell Sorter (FACS) Analyses of CD38
Expression--
Following treatment of HL-60 cells with RA,
1.5-2 × 106 cells were pelleted by centrifugation at
700 × g for 5 min. The cells were resuspended in 1 ml
of FACS buffer (phosphate-buffered saline containing 2.5% fetal bovine
serum and 0.02% NaN3) and washed once by a centrifugation
step at 14,000 × g for 20 s in a microcentrifuge and resuspended in 125 µl of FACS buffer. The cells were incubated with the primary monoclonal antibody, IB4 (1:100), for 30 min on ice
and washed once in 1 ml of FACS buffer and resuspended in 200 µl. The
secondary antibody, Alexa Fluor goat anti-mouse IgG, was added at a
dilution of 1:200, and the sample was incubated on ice after mixing and
kept in the dark to avoid bleaching. The cells were then washed twice
and resuspended in 1 ml of FACS buffer containing 1% paraformaldehyde.
The samples were sorted on a FACScalibur instrument, and data from
10,000 cells were collected and analyzed by the CELLQuest Pro software.
Measurements of Endogenous cADPR--
Acid extracts were
prepared for 5-20 × 106 cells after centrifugation
and the addition of 0.5-1 ml of cold 0.6 M perchloric acid, which could be stored at Measurement of the Enzymatic Activity of CD38--
Extracts were
prepared by centrifugation of 2.5-10 × 106 cells and
resuspension in 0.5 ml of a cold solution containing 10 mM
Tris-Cl, pH 8, and 0.1 mM phenylmethylsulfonyl fluoride.
These hypotonic cell extracts could be stored at Inhibition of CD38 Expression by Antisense
Oligonucleotides--
Morpholino antisense oligonucleotides have been
recently designed to overcome some of the known limitations of regular
antisense oligonucleotides. Morpholinos are assembled from four
subunits, each of which contains one of the four bases linked to a
six-membered morpholine ring. The subunits are joined in a specific
order by nonionic phosphorodiamidate linkages. Applications of
morpholino antisense oligonucleotides in different species indicate
that it has improved specificity and stability against nucleases
(reviewed in Refs. 27 and 28).
Morpholino antisense and sense oligonucleotides were synthesized by
Gene Tools (Philomath, OR) to target a sequence residing in the 69 bases of the 5' cap of human CD38 mRNA (GenBankTM
accession number M34461) (29). We selected the sequence 5'-GGTTGGCTGGGCGAAGATGAGGC-3', which starts 37 bases upstream of AUG
and 32 bases into the 5' cap. The sequence has minimal secondary
structure and the lowest self-complementarity, based upon the GC
content. The invert of the antisense (sense)
(5'-GCCTCATCTTCGCCCAGCCAACC-3') was used as the control. A short
stretch of each morpholino oligonucleotide (5 bases at the 3' end) was
paired to complementary DNA, and an extra 10 bases of the DNA was added
to form a 5' overhang. The DNA acts as an "adaptor" and binds
electrostatically to the delivery reagent, a weakly basic ethoxylated
polyethylenimine reagent (Gene Tools). Equimolar concentrations (1.4 µM) of the oligonucleotides and ethoxylated
polyethylenimine were first combined and incubated at room temperature
for 20 min, following which, serum-free RPMI medium (Invitrogen) was
added. HL60 cells were suspended in this solution at 1.0 × 106/ml and incubated at 37 °C in a 10% CO2
atmosphere for 3 h. The cells were then centrifuged at 3,000 rpm
for 5 min, resuspended in RPMI with 10% serum at 0.2 × 106/ml, and returned to the incubator. Following a 24-h
treatment with the oligonucleotides, RA (1.0 µM, Sigma)
was added, and the cells were harvested for analysis 3 days later.
Silencing of CD38 by Small Interfering RNA
(siRNA)--
Down-regulation of CD38 was facilitated by using the
following primers targeting two separate coding regions of CD38
mRNA: region 3 sense primer,
5'-CTCTGTCTTGGCGTCAGTATTcctgtctc-3'; region 3 antisense primer, 5'-TACTGACGCCAAGACAGAGTTcctgtctc-3';
region 27 sense primer, 5'-AGGACTGCAGCAACAACCCTTcctgtctc-3';
and region 27 antisense primer,
5'-GGGTTGTTGCTGCAGTCCTTTcctgtctc-3'. The two regions start
70 and 533 bases downstream of ATG, respectively. Bases indicated by
capital letters correspond to the region in the CD38 mRNA, while
the 8-nucleotide stretch at the 3' end, in lowercase letters, is
required for the T7 promoter primer sequence, 5'-TAATACGACTCACTATAGgagacagg-3', to hybridize to the sense and antisense primers for transcription. The two thymidines, in italics, are needed for the stability of the siRNA (30). The HiScribe RNAi
transcription kit from New England BioLabs was used to synthesize the
double-stranded siRNA. Following synthesis, the siRNA was purified
twice by ethanol precipitation and dissolved in sterile RNase-free water.
Transfection of HL60 cells was facilitated by the
TransIT-TKO Transfection Reagent (Mirus Corporation,
Madison, WI). 24 µl of the TKO reagent was first incubated with 100 µl of OPTIMEM-I medium (Invitrogen) at room temperature for 15 min
before siRNA was added. After another 15 min at room temperature, 500 µl of RPMI 1640 (with 10% calf serum) containing 0.8 × 106 cells was added. The final siRNA concentration was 125 nM, and the incubation proceeded for 4 h at 37 °C
and 5% CO2, after which 3.5 ml of RPMI 1640 (with 10%
calf serum) was added, and the incubation continued at 37 °C for
24 h. RA was added to a final concentration of 1.0 µM, and the cells were harvested 72 h later for analyses.
Tet-On Expression System for CD38--
The system was from
Clontech and contains two components. The first is
the pTet-On vector, which directs the expression of a regulatory
protein, the reverse tetracyclin-controlled transactivator. The second
is the pBI vector, which contains a bidirectional promoter, a
tetracycline-responsive element flanked by two identical promoters in
opposite orientations, allowing two genes of interest, CD38 and green
fluorescent protein in our case, to be regulated by the
tetracycline-responsive element. The inclusion of the green fluorescent
protein was intended to facilitate monitoring of transfection and for
selection of transfected clones.
Cationic liposomes were used for transfecting HL60 cells with the
pTet-On plasmid. DC-Cholesterol, L-
5 µl of the liposomal suspension was diluted in 50 µl of OPTIMEM-I
medium and incubated at room temperature for 5 min. 1.2 µg of the
ScaI-digested pTet-On plasmid was diluted in 50 µl of OPTIMEM-I medium. The DNA and liposomal dilutions were combined in
equal volumes and incubated at room temperature for 20 min. HL-60 cells
(8 × 104) in 500 µl of OPTIMEM-I medium was added
and incubated at 37 °C for 4 h. Afterward, 5 ml of RPMI 1640 (with 10% fetal calf serum) was added, and the transfected cells were
incubated at 37 °C. After two cell divisions (48 h), the cells were
resuspended in 5 ml of RPMI 1640 medium at a density of 2.0 × 104/ml with 380 µg/ml G418 (Invitrogen), the selection
antibiotic. The medium was replaced every 5 days. The cells stably
expressing reverse tetracyclin-controlled transactivator were obtained
after repeated selection with G418. Over the next 9 weeks the cells were passaged 12 times until there were virtually no dead cells in the
cultures. Control experiments show that these stably transfected cells
differentiate normally in response to RA. At that point a portion of
the cells was frozen, and the remaining cells were used for the next
transfection. All of the subsequent incubations were carried out in the
presence of 380 µg/ml G418 in the medium.
A pBI plasmid containing both green fluorescent protein and a
full-length CD38. cDNA encoding for the full-length CD38 was inserted into the one of the two multiple of the pBI plasmid at the
MluI and NheI restriction sites. The green
fluorescent protein cDNA was spliced into the other cloning site at
the SalI and PstI restriction sites. HL60 cells
were co-transfected with the construct and the pTK-Hyg
(Clontech) plasmid; the latter allowed positive selection using hygromycin. HL-60 cells containing the pTet-On vector
were transfected with the construct using cationic liposomes as
described above, and the positive clones were selected using 200 µg/ml hygromycin.
Treatment of HL-60 cells with RA induces differentiation into
granulocytes (22), which possess many of the functional characteristics of normal peripheral blood granulocytes, including phagocytosis and
chemotaxis. The underlying mechanism is largely unknown. During phagocytosis, rapid generation of superoxide anion occurs, which can be
conveniently monitored with NBT. It is a water-soluble dye, which is
converted to insoluble intracellular blue formazan by phagocytizing
neutrophils, a reaction mediated by superoxide (31, 32). Differentiated
cells that are phagocytizing are thus stained blue and black, whereas
undifferentiated cells are not stained. The NBT reaction can also be
monitored in cell suspensions by measuring the increase in absorbance
at 590 nm. Differentiated cells produce greatly increased NBT reaction
as compared with control cells. Either the absorbance changes or direct
counting of NBT staining cells was used for quantifying granulocytic differentiation.
We and others have shown that accompanying differentiation, RA also
induces expression of CD38 in HL-60 cells (19-21), which can be
conveniently measured by using FACS analyses or by measuring the
ADP-ribosyl cyclase activity of CD38 in cell extracts using the NGD
technique (21, 26). CD38 cyclizes NGD, a nonfluorescent substrate
analog of NAD, to cGDPR, a fluorescent product, which can be measured fluorimetrically.
It is generally believed that CD38 is an antigen and is mainly
expressed on the cell surface. Fig.
1A shows immunofluorescence localization of CD38 in the differentiated cells. Intact cells (
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
80 °C until processing. After thawing, the acid was removed by extraction with a solution (3:1) of
1,1,2-trichlorotrifluoroethane and tri-n-octylamine on ice as described (25). The neutral extracts were supplemented with 20 mM sodium phosphate, pH 8, and treated with an enzyme
mixture containing 0.44 unit/ml nucleotide pyrophosphatase, 0.0625 unit/ml NADase, 12.5 units/ml alkaline phosphatase, and 2 mM MgCl2 for 15-18 h at 37 °C as described
(25), to effectively remove interfering nucleotides, such as NAD,
without degrading cADPR. Subsequently, the enzymes were removed by
ultrafiltration with Centricon filters or 96-well Immobilon-P plates.
The cADPR in the extracts was measured by an enzyme cycling assay as
described previously (25). For comparison, cADPR standards were
prepared in 20 mM sodium phosphate, pH 8, and processed in
a manner identical to that of the cell extracts. This parallel
processing of cADPR standards allowed for adjustment of losses of cADPR
resulting from the procedure, which was typically about 30%. The
enzyme cycling assay was performed in 96- or 384-well plates, using
sample volumes of 100 or 40 µl, respectively. The cADPR content was
determined from the slopes of fluorescence increase of samples and
compared with those produced by cADPR standards (25). The assay of
cADPR was linear in the concentration range from 0 to 25 nM. The cADPR content was expressed in pmol/106
cells. NAD content of extracts was measured by the cycling assay before
enzyme treatment.
80 °C. For the
enzyme assay, 20 µl of the thawed extract was added to a 200-µl
reaction mixture containing 20 mM Tris, pH 8, and 50 µM NGD. The production of the fluorescent cGDPR was
measured fluorimetrically (excitation wavelength, 300 nm; emission
wavelength, 405 nm) using a fluorescence plate reader and calibrated by
with known concentrations of cGDPR (21, 26). The reactions were
measured over several hours at 25 °C, and the rates of cGDPR
production were determined from the slopes of fluorescence increase and
expressed as nmol of cGDPR formed per 106 cells.
-dioleoyl
phosphatidylethanolamine, and diphytanoyl phosphatidylethanolamine were
purchased from Avanti Polar Lipids. Formulations used were 1:1 and 1:3
(molar ratio) of L-
-dioleoyl
phosphatidylethanolamine/DC-cholesterol and diphytanoyl phosphatidylethanolamine/DC-cholesterol. 5 mg of total lipid of each
formulation were dried down and resuspended in 250 µl of distilled H2O, followed by 5 min of sonication. 250 µl of 2× phosphate-buffered saline, pH. 7.4, was added, and the
liposomes were further sonicated for 3 min.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Triton) showed ring-like immunostaining as revealed by
confocal fluorescence microscopy, consistent with surface expression.
Permeabilization with a detergent, Triton, before staining allowed
internal access and resulted in even more intense staining that
exhibited prominent intracellular structures (Fig. 1B). The
RA-induced expression of CD38 is thus not limited to the cell surface
but intracellularly throughout the cells as well, appropriate for a
signaling role.

View larger version (138K):
[in a new window]
Fig. 1.
Immunofluorescence staining of HL-60
cells. Following treatment of HL-60 cells with 1 µM
RA, 1.5-2 × 106 cells were pelleted by
centrifugation at 700 × g for 5 min. The cells were
resuspended in 1 ml of FACS buffer (see "Experimental Procedures")
and washed once by centrifugation at 14,000 × g for
20 s in a microcentrifuge. The aliquots were treated without
(
Triton) or with (+ Triton) 0.1% Triton for
permeabilization and subsequently incubated with primary (IB4) and
secondary (fluorescein-labeled anti-mouse IgG) antibodies as described
under "Experimental Procedures." The cells were fixed with 1%
paraformaldehyde in FACS buffer and added to polylysine-coated glass
coverslips before viewing with a fluorescence confocal microscope. The
left side shows bright field images corresponding to the
fluorescence images on the right.
This is supported by measuring the cellular accumulation of its
enzymatic product, cADPR, as shown in Fig.
2. At various times after RA induction,
aliquots of the culture were assayed for the enzymatic activity of CD38
(Fig. 2A), cellular contents of cADPR (Fig. 2B),
and differentiation (Fig. 2C). Parallel cultures without the
RA treatment served as control. As seen, intracellular cADPR levels in
the cells elevated progressively with a time course slightly lagging
behind the appearance of CD38 activity (19). Both CD38 expression and
cADPR accumulation, however, preceded cellular differentiation by more
than 20 h, consistent with a causal role.
|
If this were the case, inhibition of CD38 expression should lead to
inhibition of differentiation. Nicotinamide has been used as a
cell-permeant inhibitor of the NAD cyclization activity of CD38.
Mechanistically, nicotinamide actually forces the reverse of the
cyclase reaction and produces NAD from cADPR (10, 25, 33). HL-60 cells
were induced with RA and nicotinamide was added at 24 or 48 h
afterward (indicated by arrows in Fig. 3), and
endogenous cADPR levels were measured at 72 h after induction. As
can be seen in Fig. 3A,
nicotinamide produced partial inhibition of the CD38 activity. Because
the cells were washed to remove nicotinamide before the extracts were
prepared, the observed inhibition actually reflected the reduction of
CD38 expression. This was surprising, but the results were confirmed by
using FACS analyses as shown in the inset in Fig.
3A. Treatment with nicotinamide (20 mM) during the RA induction resulted in most cells exhibiting less CD38
fluorescence.
|
The cellular cADPR levels exhibited similar changes to those of the CD38 activity as shown in Fig. 3B. The extent of reduction in cADPR levels appeared more pronounced than the CD38 activity, and the levels were reduced close to the basal levels of the control cells without the RA treatment. This is likely to be due to the combined effects of the inhibition of the cyclase activity of CD38 by nicotinamide as well as the actual reduction in CD38 expression in the cells. Parallel to the reduction in cADPR and CD38, there was corresponding inhibition of cellular differentiation as shown in Fig. 3C. The inhibitory effect of nicotinamide was specific for differentiation because the treated cells were not only viable throughout the 72 h of incubation but also proliferated equally well as compared with control cells not treated with the inhibitor. Furthermore, the NAD content of the cells actually doubled, from 0.35 ± 0.05 to 0.70 ± 0.01 nmol/106 cells, after 72 h of treatment with nicotinamide, indicative of the treated cell being in an energetically favorable state.
A common method for suppressing expression of a protein is to use
antisense oligonucleotides. Morpholino oligonucleotides represent a
recent improvement of the technique and offer better specificity and
stability against nucleases than regular oligonucleotides (reviewed in
Refs. 27 and 28). Fig. 4 shows that
preincubation with the antisense oligonucleotides reduced both the
expression of CD38 and cellular differentiation to levels similar to
the control cells not treated with RA. Preincubation with the sense oligonucleotides or with just the carrier (ethoxylated
polyethylenimine) affected neither the expression of CD38 nor cellular
differentiation induced by RA. Similar to that described above for
nicotinamide, HL-60 cells proliferated equally well in the presence of
the antisense oligonucleotides as compared with control cells not
treated, indicating that its inhibitory effect was specific for
cellular differentiation.
|
In addition to antisense oligonucleotide, the RNAi technique has
recently been used for the same purpose (reviewed in Ref. 34). Two
separate regions (regions 3 and 27; see "Experimental Procedures")
in the coding sequence of CD38 were targeted. The sequences of both
regions are unique to CD38 as indicated by a sequence search. As shown
in Fig. 5A, RNAi directed
against region 27 produced about 40% inhibition of CD38 expression as
compared with control cells treated with RA alone. Differentiation in
these cells was also inhibited to a similar extent (Fig.
5B). RNAi directed against region 3 was less effective in
inhibiting either the CD38 expression or differentiation. Mock
incubation (Fig. 5B, TKO + RA) had essentially no
effect. Compared with the antisense oligonucleotide technique (Fig. 4),
the RNAi method appeared to be less effective. The reason for this is
unknown but may be related to the fact that the RNAi technique relies
on the endogenous RNA degradation pathway being fully functioning,
which may not be the case in HL-60 cells. Alternatively, the two
targeted regions on the mRNA, which were selected because of their
unique sequence, may not be optimal for degradation. The exact cause
for the inefficiency of the RNAi was not investigated further.
Nevertheless, there appeared to be a remarkably good correlation
between the extent of inhibition of CD38 expression and differentiation
(detailed below).
|
A more direct test for the causal role of CD38 is to enhance its
expression artificially without activating the endogenous RA signaling
pathway. This was achieved by transfecting HL-60 cells with the Tet-On
expression construct containing full-length CD38. The expression system
can then be activated by treating the transfected HL-60 cells with
doxycycline. We first verified that doxycycline itself has no effect on
either differentiation or CD38 expression of control HL-60 cells
without the construct. Fig. 6 shows that
in cells transfected with the construct, treatment with doxycycline
induced expression of CD38 as shown by FACS analyses. This was
confirmed by measuring CD38 enzymatic activity in cell extracts as
compared with control cells not activated by RA (Fig. 6B,
lower panel). The extent of increase in CD38 activity
induced by doxycycline is about 40% of the activity of either control or transfected cells treated with RA. It is clear that even though the
artificial Tet-On expression system was not as effective as the natural
system activated by RA, its activation by doxycycline was able to
induce differentiation in the transfected cell to an extent similar to
that observed for the increase in CD38 activity.
|
That there is a direct correlation between the extent of CD38
expression and cellular differentiation is shown more clearly in Fig.
7, where the results of the four
different treatments described above are normalized to that induced by
RA alone and plotted together. Thus, the antisense oligonucleotide
treatment, which blocked CD38 expression most effectively, also
inhibited differentiation most effectively. The regression line shown
has an r2 value of 0.976, close to perfect
linearity.
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study four different treatments were used to block CD38 in HL-60 cells, which include nicotinamide, a chemical inhibitor, an RNAi technique targeting two separate regions of the coding sequence of CD38, and antisense morpholino oligonucleotides targeting the 5' cap of the CD38 mRNA. All four treatments led to inhibition of granulocytic differentiation to varying degrees. Conversely, two different treatments that enhanced CD38 expression, namely, treatment with a natural inducer, RA, or artificially using doxycline to activate the Tet-On expression system, both led to induction of differentiation. In fact, the correlation between CD38 expression and differentiation was close to perfect as shown in Fig. 7. The results of the nicotinamide treatment were not included in the plot because the chemical has dual effects of not only inhibiting CD38 expression but also blocking its enzymatic activity. The regression line of the correlation extrapolated to an intercept of about 10% CD38 expression, suggesting that CD38 expression must surpass a threshold level before differentiation can be activated. That the nicotinamide treatment affected CD38 expression was unexpected but may suggest the existence of a positive feedback mechanism during the RA-induced differentiation, by which the increase in cADPR levels positively stimulated the expression.
The exact mechanism of how CD38 expression can induce differentiation remains to be elucidated but is likely to be related to the accumulation of cADPR, a Ca2+ messenger, and an enzymatic product of CD38. Consistent with this notion is the time course measurements (Fig. 2) showing cADPR accumulation lagged slightly behind CD38 expression but preceded prominently cellular differentiation (19). Further support comes from the results of the nicotinamide treatment, which showed that the inhibition of differentiation correlated better with cADPR levels than with CD38 expression (Fig. 3). That cADPR level may be the causal factor is also consistent with the observation that a threshold of CD38 expression appeared to be required (Fig. 7), because it is likely that cADPR production must exceed degradation before it can accumulate and exert its signaling function.
A wide range of physiological functions have now been shown to be mediated by the Ca2+ mobilizing activity of cADPR in cells spanning three biological kingdoms, from protist, to plant to animal (reviewed in Refs. 4, 8, and 9). Although the presence of cADPR-sensitive Ca2+ stores in HL-60 cells has not yet been reported, it is likely to be present because a similar cell type, the mouse neutrophil, has been shown to possess them, the mobilization of which is involved in the chemotactic response of the cells (16). Also, HL-60 cells have been shown to possess Ca2+ stores sensitive to nicotinic acid adenine dinucleotide phosphate (35), another Ca2+ messenger that is also an enzymatic product of CD38 (10).
The fact that cADPR, the enzymatic product of CD38, accumulates inside HL-60 cells indicates that CD38 is expressed intracellularly. This was directly shown using immunofluorescence staining in this study (Fig. 1). The results are consistent with previous localization of CD38 to various intracellular organelles by immunoelectromicroscopy in brain (36) as well as to the nuclear envelope of cultured cells (37) and hepatocytes (38). It is thus not appropriate to think of CD38 as an antigen expressed solely on the cell surface, although it is of interest to note that even surface CD38 can exert its intracellularly signaling function by catalytically transporting cADPR into cells and also via the endocytic pathway (reviewed in Ref. 39).
Whether CD38 has a role in human neutrophil differentiation in
vivo remains to be demonstrated. CD38 has already been shown to be
important in mediating proliferation of HeLa cells (13), a human cell
line, and expansion of human hemopoietic progenitors (14, 15). On the
other hand, neutrophils in CD38 knockout mice exhibit a severe defect
in their chemotactic response to formyl peptides but otherwise appear
to differentiate normally (16). When considering functions in
vivo, the well documented presence of many compensatory mechanisms
must also be considered. Indeed, ADP-ribosyl cyclase activity can still
be detected in some tissues of the CD38 knockout mice. Also, cADPR
contents in some tissues, especially in brain and heart, remain close
to normal (16), suggesting the existence of a redundant cyclase present in the animal in addition to CD38. Another rather dramatic example is a
recent report showing that the hormone, estrogen, in female mice can
protect them from developing cardiac hypertrophy when their genes for
the FK506 binding proteins are disrupted, whereas male knockout mice,
lacking estrogen, exhibit a prominent defect (40). It is thus
conceivable that some other compensatory mechanisms in the CD38
knockout mice may allow their neutrophils to develop.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Santina Bruzzone for help in immunofluorescence staining and Fabio Malavasi (Universita di Torino, Italy) for generously providing the IB4 monoclonal antibody.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants GM60333 and GM61568 (to H. C. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Pharmacology,
321 Church St. SE, 4-145 Jackson Hall, Univ. of Minnesota, Minneapolis, MN 55455. Tel.: 612-625-7120; Fax:
612-625-0991; E-mail: leehc@tc.umn.edu.
Published, JBC Papers in Press, October 16, 2002, DOI 10.1074/jbc.M209313200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: cADPR, cyclic ADP-ribose; NGD, nicotinamide guanine dinucleotide; cGDPR, cyclic GDP-ribose; FACS, fluorescence-activated cell sorter; NBT, nitro blue tetrazolium; RA, retinoic acid; RNAi, RNA interference; siRNA, small interfering RNA.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Reinherz, E. L.,
Kung, P. C.,
Goldstein, G.,
Levey, R. H.,
and Schlossman, S. F.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
1588-1592 |
| 2. | States, D. J., Walseth, T. F., and Lee, H. C. (1992) Trends Biochem. Sci. 17, 495[Medline] [Order article via Infotrieve] |
| 3. | Lee, H. C. (2000) Chem. Immunol. 75, 39-59[Medline] [Order article via Infotrieve] |
| 4. | Lee, H. C. (1999) Biol. Chem. 380, 785-793[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Clapper, D. L.,
Walseth, T. F.,
Dargie, P. J.,
and Lee, H. C.
(1987)
J. Biol. Chem.
262,
9561-9568 |
| 6. |
Lee, H. C.,
Walseth, T. F.,
Bratt, G. T.,
Hayes, R. N.,
and Clapper, D. L.
(1989)
J. Biol. Chem.
264,
1608-1615 |
| 7. | Lee, H. C., Aarhus, R., and Levitt, D. (1994) Nat. Struct. Biol. 1, 143-144[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Lee, H. C.
(1997)
Physiol. Rev.
77,
1133-1164 |
| 9. | Lee, H. C. (2001) Annu. Rev. Pharmacol. Toxicol. 41, 317-345[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Aarhus, R.,
Graeff, R. M.,
Dickey, D. M.,
Walseth, T. F.,
and Lee, H. C.
(1995)
J. Biol. Chem.
270,
30327-30333 |
| 11. |
Lee, H. C.,
and Aarhus, R.
(1995)
J. Biol. Chem.
270,
2152-2157 |
| 12. | Lee, H. C. (2000) J. Membr. Biol. 173, 1-8[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Zocchi, E.,
Daga, A.,
Usai, C.,
Franco, L.,
Guida, L.,
Bruzzone, S.,
Costa, A.,
Marchetti, C.,
and De Flora, A.
(1998)
J. Biol. Chem.
273,
8017-8024 |
| 14. |
Podesta, M.,
Zocchi, E.,
Pitto, A.,
Usai, C.,
Franco, L.,
Bruzzone, S.,
Guida, L.,
Bacigalupo, A.,
Scadden, D. T.,
Walseth, T. F., De,
Flora, A.,
and Daga, A.
(2000)
FASEB J.
14,
680-690 |
| 15. | Zocchi, E., Podesta, M., Pitto, A., Usai, C., Bruzzone, S., Franco, L., Guida, L., Bacigalupo, A., and De Flora, A. (2001) FASEB J. 15, 29 |
| 16. | Partida-Sanchez, S., Cockayne, D., Monard, S., Jacobson, E. L., Oppenheimer, N., Garvy, B., Kusser, K., Goodricj, S., Howard, M., Harmsen, A., Randall, T., and Lund, F. E. (2001) Nat. Med. 7, 1209-1216[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Okamoto, H. (1999) Mol. Cell. Biochem. 193, 115-118[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Fukushi, Y.,
Kato, I.,
Takasawa, S.,
Sasaki, T.,
Ong, B. H.,
Sato, M.,
Ohsaga, A.,
Sato, K.,
Shirato, K.,
Okamoto, H.,
and Maruyama, Y.
(2001)
J. Biol. Chem.
276,
649-655 |
| 19. | Takahashi, K., Kukimoto, I., Tokita, K., Inageda, K., Inoue, S., Kontani, K., Hoshino, S., Nishina, H., Kanaho, Y., and Katada, T. (1995) FEBS Lett. 371, 204-208[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Kontani, K.,
Nishina, H.,
Ohoka, Y.,
Takahashi, K.,
and Katada, T.
(1993)
J. Biol. Chem.
268,
16895-16898 |
| 21. | Graeff, R. M., Mehta, K., and Lee, H. C. (1994) Biochem. Biophys. Res. Commun. 205, 722-727[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Collins, S. J.
(1987)
Blood
70,
1233-1244 |
| 23. | Ohguchi, K., Nakashima, S., and Nozawa, Y. (1999) Biochim. Biophys. Acta 1439, 215-217[Medline] [Order article via Infotrieve] |
| 24. | Munshi, C., and Lee, H. C. (1997) Protein Expression Purif. 11, 104-110[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Graeff, R., and Lee, H. C. (2002) Biochem. J. 361, 379-384[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Graeff, R. M.,
Walseth, T. F.,
Fryxell, K.,
Branton, W. D.,
and Lee, H. C.
(1994)
J. Biol. Chem.
269,
30260-30267 |
| 27. | Kipshidze, N., Moses, J., Shankar, L. R., and Leon, M. (2001) Curr. Opin. Mol. Ther. 3, 265-277[Medline] [Order article via Infotrieve] |
| 28. | Iversen, P. L. (2001) Curr. Opin. Mol. Ther. 3, 235-238[Medline] [Order article via Infotrieve] |
| 29. | Jackson, D. G., and Bell, J. I. (1990) J. Immunol. 144, 2811-2815[Abstract] |
| 30. | Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001) Nature 411, 494-498[CrossRef][Medline] [Order article via Infotrieve] |
| 31. |
Collins, S. J.,
Ruscetti, F. W.,
Gallagher, R. E.,
and Gallo, R. C.
(1979)
J. Exp. Med.
149,
969-974 |
| 32. |
Breitman, T. R.,
Selonick, S. E.,
and Collins, S. J.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
2936-2940 |
| 33. |
Kim, H.,
Jacobson, E. L.,
and Jacobson, M. K.
(1993)
Science
261,
1330-1333 |
| 34. | Ullu, E., Djikeng, A., Shi, H., and Tschudi, C. (2002) Philos. Trans. R. Soc. Lond-Biol. Sci. 357, 65-70[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Yusufi, A. N., Cheng, J., Thompson, M. A., Chini, E. N., and Grande, J. P. (2001) Biochem. J. 353, 531-536[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Yamada, M., Mizuguchi, M., Otsuka, N., Ikeda, K., and Takahashi, H. (1997) Brain Res. 756, 52-60[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Adebanjo, O. A., Anandatheerthavarada, H. K., Koval, A. P., Moonga, B. S., Biswas, G., Sun, L., Sodam, B. R., Bevis, P. J. R., Huang, C. L. H., Epstein, S., Lai, F. A., Avadhani, N. G., and Zaidi, M. (1999) Nat. Cell Biol. 1, 409-414[CrossRef][Medline] [Order article via Infotrieve] |
| 38. |
Khoo, K. M.,
Han, M.-K.,
Park, J. B.,
Chae, S. W.,
Kim, U.-H.,
Lee, H. C.,
Bay, B. H.,
and Chang, C. F.
(2000)
J. Biol. Chem.
275,
24807-24817 |
| 39. | De Flora, A., Guida, L., Franco, L., and Zocchi, E. (1997) Int. J. Biochem. Cell Biol. 29, 1149-1166[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Xin, H. B., Senbonmatsu, T., Cheng, D. S., Wang, Y. X., Copello, J. A., Ji, G. J., Collier, M. L., Deng, K. Y., Jeyakumar, L. H., Magnuson, M. A., Inagami, T., Kotlikoff, M. I., and Fleischer, S. (2002) Nature 416, 273-274[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
P. Munoz, M. Mittelbrunn, H. de la Fuente, M. Perez-Martinez, A. Garcia-Perez, A. Ariza-Veguillas, F. Malavasi, M. Zubiaur, F. Sanchez-Madrid, and J. Sancho Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse Blood, April 1, 2008; 111(7): 3653 - 3664. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kim, H. H. Kim, J. H. Kim, Y. H. Choi, Y. H. Kim, and J. Cheong Chemokine stromal cell-derived factor-1 induction by C/EBP{beta} activation is associated with all-trans-retinoic acid-induced leukemic cell differentiation J. Leukoc. Biol., November 1, 2007; 82(5): 1332 - 1339. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Soares, M. Thompson, T. White, A. Isbell, M. Yamasaki, Y. Prakash, F. E. Lund, A. Galione, and E. N. Chini NAADP as a second messenger: neither CD38 nor base-exchange reaction are necessary for in vivo generation of NAADP in myometrial cells Am J Physiol Cell Physiol, January 1, 2007; 292(1): C227 - C239. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Johnson, E. L. Ford, E. Bernal-Mizrachi, K. L. Kusser, D. S. Luciani, Z. Han, H. Tran, T. D. Randall, F. E. Lund, and K. S. Polonsky Suppressed insulin signaling and increased apoptosis in CD38-null islets. Diabetes, October 1, 2006; 55(10): 2737 - 2746. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Graeff, Q. Liu, I. A. Kriksunov, Q. Hao, and H. C. Lee Acidic Residues at the Active Sites of CD38 and ADP-ribosyl Cyclase Determine Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Synthesis and Hydrolysis Activities J. Biol. Chem., September 29, 2006; 281(39): 28951 - 28957. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. O. Hassa, S. S. Haenni, M. Elser, and M. O. Hottiger Nuclear ADP-Ribosylation Reactions in Mammalian Cells: Where Are We Today and Where Are We Going? Microbiol. Mol. Biol. Rev., September 1, 2006; 70(3): 789 - 829. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Brailoiu, D. Churamani, V. Pandey, G. C. Brailoiu, F. Tuluc, S. Patel, and N. J. Dun Messenger-specific Role for Nicotinic Acid Adenine Dinucleotide Phosphate in Neuronal Differentiation J. Biol. Chem., June 9, 2006; 281(23): 15923 - 15928. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Santella NAADP: A New Second Messenger Comes of Age Mol. Interv., April 1, 2005; 5(2): 70 - 72. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thompson, H. Barata da Silva, W. Zielinska, T. A. White, J. P. Bailey, F. E. Lund, G. C. Sieck, and E. N. Chini Role of CD38 in myometrial Ca2+ transients: modulation by progesterone Am J Physiol Endocrinol Metab, December 1, 2004; 287(6): E1142 - E1148. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shoda, Y. Inada, A. Tsuji, H. Kusama, T. Ueda, T. Ikegami, H. Suzuki, Y. Sugiyama, D. E. Cohen, and N. Tanaka Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPAR{alpha}-mediated redistribution of ABCB4 J. Lipid Res., October 1, 2004; 45(10): 1813 - 1825. [Abstract] [Full Text] [PDF] |
||||